These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28502299)

  • 41. Tumor-associated macrophages promote human hepatoma Huh-7 cell migration and invasion through the Gli2/IGF-II/ERK1/2 axis by secreting TGF-β1.
    Liu M; Zhong YB; Shao J; Zhang C; Shi C
    Cancer Biol Ther; 2020 Nov; 21(11):1041-1050. PubMed ID: 33081566
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
    Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
    Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
    [TBL] [Abstract][Full Text] [Related]  

  • 43. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Li J; Shi L; Zhang X; Sun B; Yang Y; Ge N; Liu H; Yang X; Chen L; Qian H; Wu M; Yin Z
    Oncotarget; 2016 Jan; 7(3):2646-59. PubMed ID: 26544731
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sorafenib blocks the HIF-1α/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells.
    Xu M; Zheng YL; Xie XY; Liang JY; Pan FS; Zheng SG; Lü MD
    DNA Cell Biol; 2014 May; 33(5):275-81. PubMed ID: 24611881
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells.
    Muche S; Kirschnick M; Schwarz M; Braeuning A
    Anticancer Res; 2014 Sep; 34(9):4677-83. PubMed ID: 25202044
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EGF reverses multi-drug resistance via the p-ERK pathway in HepG2/ADM and SMMC7721/ADM hepatocellular carcinoma models.
    Yan F; Bai LP; Gao H; Zhu CM; Lin L; Kang XP
    Asian Pac J Cancer Prev; 2014; 15(6):2619-23. PubMed ID: 24761873
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
    Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
    Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Endogenous IFN-β maintains M1 polarization status and inhibits proliferation and invasion of hepatocellular carcinoma cells].
    Xie C; Guo B; Liu C; Lin Y; Wu B; Wang Q; Li Z; Tu Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Jul; 32(7):865-9. PubMed ID: 27363262
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
    Gu HR; Park SC; Choi SJ; Lee JC; Kim YC; Han CJ; Kim J; Yang KY; Kim YJ; Noh GY; No SH; Jeong JH
    Clin Mol Hepatol; 2015 Mar; 21(1):49-59. PubMed ID: 25834802
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib.
    Chiba N; Ozawa Y; Hikita K; Okihara M; Sano T; Tomita K; Takano K; Kawachi S
    Oncol Rep; 2017 Apr; 37(4):2270-2276. PubMed ID: 28260092
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
    Nojiri K; Sugimoto K; Shiraki K; Tameda M; Inagaki Y; Ogura S; Kasai C; Kusagawa S; Yoneda M; Yamamoto N; Takei Y; Nobori T; Ito M
    Int J Oncol; 2013 Jan; 42(1):101-8. PubMed ID: 23123700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma.
    Liu L; Lu L; Zheng A; Xie J; Xue Q; Wang F; Wang X; Zhou H; Tong X; Li Y; Zhu X; Wu G
    Oncotarget; 2017 Feb; 8(8):13666-13677. PubMed ID: 28099144
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
    J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overexpression of RIP140 suppresses the malignant potential of hepatocellular carcinoma by inhibiting NF‑κB‑mediated alternative polarization of macrophages.
    Hu YC; Yi ZJ; Zhou Y; Li PZ; Liu ZJ; Duan SG; Gong JP
    Oncol Rep; 2017 May; 37(5):2971-2979. PubMed ID: 28393222
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HBx Modulates Drug Resistance of Sorafenib-Resistant Hepatocellular Carcinoma Cells.
    Liu Y; Liu X; Luo M; Li Y; Li H
    Discov Med; 2023 Dec; 35(179):1035-1042. PubMed ID: 38058068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
    Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effect of Atractylodes macrocephala polysaccharide on proliferation and invasion of hepatocellular carcinoma cells
    Zhu Y; Li C; Lin X; Sun J; Cheng Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Oct; 39(10):1180-1185. PubMed ID: 31801717
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway.
    Peng YY; He YH; Chen C; Xu T; Li L; Ni MM; Meng XM; Huang C; Li J
    Cancer Lett; 2016 Jun; 376(1):10-21. PubMed ID: 26975630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.